ARKG vs IXJ

Key Takeaways

• ARKG is an actively managed thematic ETF targeting the genomics revolution with concentrated exposure to innovative, often smaller biotechnology companies, while IXJ is a passively managed fund providing broad exposure to the global healthcare sector through large-cap holdings.
• ARK Genomic Revolution ETF (ARKG) maintains 30-60 holdings with a focus on high-conviction genomics-related names, resulting in higher volatility and thematic concentration compared to the more diversified ~110 holdings in iShares Global Healthcare ETF (IXJ).
• The expense ratio for ARK Genomic Revolution ETF (ARKG) stands at 0.75%, significantly higher than the 0.38% for iShares Global Healthcare ETF (IXJ), reflecting the active management premium versus passive indexing.
• Sector allocation in ARK Genomic Revolution ETF (ARKG) centers almost exclusively on healthcare with heavy emphasis on biotechnology and life sciences tools, whereas iShares Global Healthcare ETF (IXJ) delivers balanced global exposure across pharmaceuticals, biotechnology, and healthcare equipment and services.
• ARK Genomic Revolution ETF (ARKG) employs active stock selection and rebalancing based on ARK Investment Management's research-driven process, contrasting with the rules-based, market-cap weighted methodology of iShares Global Healthcare ETF (IXJ)'s underlying index.
• Investors seeking targeted innovation exposure may consider ARK Genomic Revolution ETF (ARKG) for its thematic purity, while those prioritizing cost efficiency, diversification, and broad sector representation often favor iShares Global Healthcare ETF (IXJ).

Introduction

ARK Genomic Revolution ETF (ARKG) and iShares Global Healthcare ETF (IXJ) offer distinct approaches to healthcare investing, making them relevant for comparison in the current environment of advancing biotechnology and sustained demand for global health solutions. ARK Genomic Revolution ETF (ARKG) pursues a concentrated, active thematic strategy centered on genomics innovations, while iShares Global Healthcare ETF (IXJ) delivers broad, passive exposure to the entire healthcare sector worldwide. These ETFs do not compete directly but serve as alternative vehicles for investors targeting similar long-term goals of capital appreciation in healthcare, with differences in risk, cost, and strategy that influence positioning across market cycles.

ARK Genomic Revolution ETF (ARKG) Overview

ARK Genomic Revolution ETF (ARKG) is an actively managed exchange-traded fund launched in 2014 that seeks long-term growth of capital by investing primarily in equity securities of companies relevant to the genomics revolution. The fund typically holds between 30 and 60 securities, with top positions including 10x Genomics Inc. (TXG), Twist Bioscience Corp. (TWST), Tempus AI Inc. (TEM), CRISPR Therapeutics AG (CRSP), and Personalis Inc. (PSNL). Its strategy focuses on innovative areas such as gene therapy, bioinformatics, and molecular medicine, resulting in heavy allocation to healthcare—particularly biotechnology and life sciences tools—with modest exposure to information technology. The expense ratio is 0.75%, and the non-diversified structure allows for concentrated bets on high-conviction names selected through ARK Investment Management's research process, with periodic rebalancing driven by evolving thematic views.

iShares Global Healthcare ETF (IXJ) Overview

iShares Global Healthcare ETF (IXJ) is a passively managed exchange-traded fund launched in 2001 that seeks to track the performance of the S&P Global 1200 Health Care (Sector) Capped Index. The fund holds approximately 110 securities and employs representative sampling to replicate index characteristics. Top holdings typically include Eli Lilly & Co. (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), UnitedHealth Group Inc. (UNH), and Merck & Co. Inc. (MRK), emphasizing large-cap pharmaceutical, biotechnology, and healthcare equipment companies. Sector allocations break down primarily into pharma, biotech and life sciences alongside healthcare equipment and services, with global geographic exposure led by the United States. The expense ratio is 0.38%, and the fund follows a rules-based, market-capitalization-weighted methodology with low turnover and semi-annual distributions.

Industry and Thematic Backdrop

The healthcare sector continues to benefit from long-term structural drivers including aging populations, advances in precision medicine, and expanding global access to treatments. Genomics and biotechnology innovations represent a high-growth subset within this landscape, supported by ongoing research breakthroughs and regulatory pathways for novel therapies. Broader healthcare faces macroeconomic influences such as interest rate expectations, healthcare policy developments, and capital allocation priorities across developed markets. Risks include regulatory scrutiny on drug pricing, clinical trial outcomes, and competition within biotech. Capital flows into the sector often favor established large-cap players during periods of economic uncertainty while thematic innovation strategies attract growth-oriented investors seeking exposure to disruptive technologies.

Performance and Positioning Comparison

In recent market cycles, ARK Genomic Revolution ETF (ARKG) has exhibited higher volatility due to its concentrated thematic bets and smaller-cap tilt, often amplifying moves tied to biotech earnings reports and innovation milestones. iShares Global Healthcare ETF (IXJ) has demonstrated more stable behavior consistent with its large-cap, diversified global healthcare exposure, showing resilience through sector rotations and interest rate shifts. Relative positioning highlights ARK Genomic Revolution ETF (ARKG)'s sensitivity to genomics-specific catalysts versus iShares Global Healthcare ETF (IXJ)'s broader participation in pharmaceutical and provider performance across economic environments. Both funds respond to macro factors including regulatory changes and healthcare spending trends, though the active thematic approach in ARK Genomic Revolution ETF (ARKG) introduces greater dispersion from broad sector benchmarks.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Professional and retail investors seeking data-driven insights into ETFs like ARK Genomic Revolution ETF (ARKG) and iShares Global Healthcare ETF (IXJ) may find the platform valuable for ongoing research.

Tickeron AI Verdict

Based on structural characteristics including lower expense ratio, greater diversification across holdings and geographies, and passive efficiency, Tickeron’s AI would likely favor iShares Global Healthcare ETF (IXJ) in the current environment for most investors seeking healthcare exposure with moderated risk and cost efficiency. ARK Genomic Revolution ETF (ARKG) could appeal in scenarios prioritizing high-conviction thematic innovation, though its higher fees and concentration warrant careful consideration of risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations